DRW Securities LLC Makes New $877,000 Investment in Pfizer Inc. (NYSE:PFE)

DRW Securities LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 33,096 shares of the biopharmaceutical company's stock, valued at approximately $877,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Nordea Investment Management AB boosted its stake in shares of Pfizer by 36.1% in the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after buying an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI increased its position in shares of Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after purchasing an additional 159,984 shares during the last quarter. Copley Financial Group Inc. bought a new stake in shares of Pfizer during the 3rd quarter worth $577,000. Mcdonald Partners LLC boosted its holdings in shares of Pfizer by 9.9% in the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after buying an additional 9,963 shares during the last quarter. Finally, Merit Financial Group LLC increased its holdings in Pfizer by 60.8% during the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock worth $3,395,000 after buying an additional 48,397 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of research firms recently commented on PFE. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, UBS Group reduced their target price on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and an average target price of $31.07.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Trading Up 0.4 %

Shares of PFE traded up $0.09 during midday trading on Monday, hitting $22.00. The stock had a trading volume of 24,009,534 shares, compared to its average volume of 40,174,702. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock's 50 day moving average is $25.25 and its 200 day moving average is $26.38. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The firm has a market cap of $124.77 billion, a PE ratio of 15.60, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the business earned $0.10 earnings per share. Pfizer's revenue was up 24.7% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.